Cooperative Agreement ASTWH170059

This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...

The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...

Federal Cooperative Agreement Summary George Washington University received a $2.1 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research evaluating oxytocin (OXT), an FDA-approved medication, as a novel therapeutic intervention for opioid-induced respiratory depression (OIRD). The research initiative, awarded July 1, 2025, with completion expected June 30, 2027, addresses the critical...

PROMOTE Study: Shared Decision Making Implementation in Opioid Treatment Programs The University of Pittsburgh received a $488,334 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the PERSONALIZED METHADONE TREATMENT (PROMOTE) study. The award, obligated on September 30, 2025, with completion targeted for August 31, 2027, supports a hybrid type 3 implementation-effectiveness trial designed to adapt and...

Federal Project Grant Award Summary Columbia University received a $1,000,028 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective September 1, 2025 through August 31, 2027. The award funds an R61/R33 effectiveness trial of WINGS+++ (Women Initiating New Goals of Safety), a mobile health intervention designed to address the intersection of opioid use disorder (OUD), substance use disorders (SUD), intimate...

Wisconsin Opioid Prevention and Treatment Research Network (WI OPTRN) The University of Wisconsin System was awarded $349,112 under a Cooperative Agreement by the Centers for Disease Control and Prevention's National Center for Environmental Health on September 30, 2025, under the Injury Prevention and Control Research and State and Community Based Programs (CFDA 93.136). The award supports the Wisconsin Opioid Prevention and Treatment Research Network (WI OPTRN), with a performance period...

Federal Grant Award Summary: PROUD2ACT The University of Oklahoma Health Sciences Center received a $348,756 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate a mobile health intervention addressing opioid use disorder recovery in the postpartum period. Awarded on June 1, 2025, with a completion date of May 31, 2030, this research initiative will produce a smartphone-based intervention...

Rhode Island Hospital received a $1,033,962 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective September 15, 2025, through August 31, 2027. The award supports adaptation and evaluation of the Safe and Health Experiences (SHE) Program for use in opioid use disorder (OUD) care settings, designated as SHE-OUD. The SHE program is a one-session, modular computer-based screening, brief intervention, and...

Federal Project Grant Award Summary The Medical University of South Carolina received a $182,249 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) effective July 15, 2025, through June 30, 2029. This award supports the implementation and evaluation of EMPWR (Empowering Pregnant Women Receiving Medications for Opioid Use Disorder), a digitally enhanced intervention designed to improve buprenorphine treatment retention among...

Grant Award Summary The University of Illinois received a $109,076 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective January 25, 2026, through January 24, 2030. This award supports research investigating the relationship between ovarian steroid hormones and cannabis use patterns in reproductive-aged females. The project employs novel computational modeling approaches, specifically generalized additive mixed...